Serafin Morales

Oncology — Hospital Universitari Arnau de Vilanova, Spain

LeadR Profile

1 124 ScienceLeadR Reputation 1124
Network Map

Oncology

Subspecialties: Biochemistry - Dermatology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1991 - 2026

Source: PubMed

Hospital Universitari Arnau de Vilanova

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 173

Citations

Citations: 7 769 1st author: 19 Last author: 1 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Concordance analysis of non-invasive techniques for PIK3CA and ESR1 mutations in advanced HR+/HER2- breast cancer: the CANIPE study.
breast neoplasms, neoplasms, breast, therapeutics, mutation
NPJ Precis Oncol20260
Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.
triple negative breast neoplasms, breast neoplasms, lymphocytes, lymphocytes, tumor-infiltrating, neoplasms, drug therapy, drug-related side effects and adverse reactions, lymph, breast, chemotherapy
Nat Med Top journal20260
Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results.
breast neoplasms, neoplasms, breast, receptors, progesterone, progesterone
NPJ Breast Cancer20260
Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.
breast neoplasms, neoplasms, breast, therapeutics, trastuzumab
Clin Cancer Res20250
Addition of ipatasertib to dual anti-HER2 maintenance therapy in HER2-positive metastatic breast tumors with PIK3CA mutations: the phase 1b SOLTI-1507 IPATHER trial.
safety, breast neoplasms, neoplasms, maintenance, breast, therapeutics, diarrhea, mutation, trastuzumab
Clin Cancer Res20250

Clinical Studies 46

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 19
Phase 2 17
Phase 1 5
Early Phase 1 2
Phase 1/Phase 2 2
N/A 1

By status:

Completed 26
Active not recruiting 9
Recruiting 6
Not yet recruiting 2
Unknown 2
Terminated 1

By type:

Interventional 45
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 4
multicentricup10 39

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase Ib III Study of Capivasertib CDK4 6 Inhibitors Fulvestrant as Treatment for Advanced Metastatic HR HER2 Breast Cancer (CAPItello 292)
2023-504997-39-00 — genes, epidermal growth factor, fulvestrant, growth, breast neoplasms, neoplasms, hormones, receptors, growth factor, breast, therapeutics
Phase 3Active not recruiting2021
NoLEEta Phase III non inferiority trial of chemotherapy de escalation in hormone receptorpositive Her2 negative intermediate risk early breast cancer treated with Ribociclib (LEE 011) in the adjuvant setting
2025-520979-13-00 — breast neoplasms, neoplasms, drug therapy, hormones, chemotherapy, adjuvant, breast, chemotherapy
Phase 3Not yet recruiting2025
A proof of concept study to evaluate treatments efficacy by monitoring Minimal Residual Disease using ctDNA in HR positive HER2 negative early breast cancer population
2023-505661-89-00 — epidermal growth factor, growth, breast neoplasms, neoplasms, hormones, proof of concept study, receptors, growth factor, breast, neoplasm, residual, therapeutics
Phase 2Recruiting2024
First in Human Study of OKI 219 Alone and in Combination with Other Therapies in Patients with Solid Tumors Breast Cancer
2023-508435-31-00 — breast neoplasms, neoplasms, breast, therapeutics
Phase 1Recruiting2024
A Randomized Multicenter Placebo controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2 neu Peptide GLSI 100 (GP2 GM CSF) in HER2 neu Positive Subjects with Residual Disease or High Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab based Therapy (FLAMINGO 01)
2023-504323-25-01 — granulocyte-macrophage colony-stimulating factor, safety, breast neoplasms, polymerase chain reaction, neoplasms, breast, therapeutics, trastuzumab
Phase 3Not yet recruiting2024

LeadR Networks

Main global connection map